Cyclins are a family of proteins that control the progression of cells through the cell cycle by activating cyclin-dependent kinase (CDK) enzymes. They derive their name from the fact that their concentrations oscillate in a cyclical fashion during the cell cycle, rising during specific phases and then rapidly declining, primarily through ubiquitin-mediated proteasomal degradation.
Function and Mechanism: Cyclins act as regulatory subunits for CDKs. CDKs are constitutively present in the cell but are largely inactive without an associated cyclin. The binding of a specific cyclin to its corresponding CDK induces a conformational change in the CDK, exposing its active site and making it catalytically active. The activated cyclin-CDK complex then phosphorylates target proteins, thereby orchestrating the events necessary for cell cycle progression.
Types and Roles in the Cell Cycle: Different cyclins are expressed at different stages of the cell cycle, ensuring an orderly progression through phases:
- G1 Cyclins (e.g., Cyclin D): Regulate the G1 phase and promote entry into S phase. Cyclin D partners with CDK4 and CDK6.
- G1/S Cyclins (e.g., Cyclin E): Promote the transition from G1 to S phase and initiate DNA replication. Cyclin E partners with CDK2.
- S Cyclins (e.g., Cyclin A): Drive DNA replication during S phase and help regulate entry into mitosis. Cyclin A partners with CDK2 and CDK1.
- M Cyclins (e.g., Cyclin B): Promote the entry into M phase (mitosis) and the events of mitosis. Cyclin B partners with CDK1.
Regulation: The precise timing and activity of cyclin-CDK complexes are crucial for proper cell division. This regulation involves:
- Synthesis and Degradation: Cyclins are synthesized at specific points in the cell cycle and rapidly degraded at the end of their respective phases, primarily by the anaphase-promoting complex/cyclosome (APC/C) via ubiquitination, which targets them for proteasomal destruction.
- CDK Phosphorylation/Dephosphorylation: CDKs themselves can be regulated by phosphorylation at specific sites, either activating or inhibiting their activity.
- CDK Inhibitors (CKIs): Proteins like p21, p27, and p16 directly bind to and inhibit cyclin-CDK complexes, acting as checkpoints to halt the cell cycle if conditions are unfavorable or DNA damage is detected.
Clinical Significance: Dysregulation of cyclin levels or activity is frequently observed in cancer. Overexpression of certain cyclins (e.g., Cyclin D1) or mutations that prevent their degradation can lead to uncontrolled cell proliferation and contribute to tumor development. Therefore, cyclins and CDKs are important targets for anti-cancer therapies.